Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure.
T ransthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized etiology of heart failure (HF) and is no longer considered an untreatable disease. Data that demonstrate survival and hospitalization benefit for the TTR stabilizer, tafamidis, and ongoing development of novel therapeutics create urgency for clinicians to recognize the disease and refer patients for therapy (1) . However, determining the most appropriate management plan requires an understanding of a patient's prognosis. In the last decade, increasing investigation of patients with ATTR-CM has led to recognition of many prognostic factors across numerous domains. We review the prognostic factors that have been identified in patients with ATTR-CM to provide the treating clinician a framework to : 1) appropriately counsel patients about the natural history of the disease; and 2) use prognostic information to guide management plans. (2) . In addition to mortality, presence of NYHA functional class III or IV HF was found to be an independent risk factor for a composite of adverse cardiovascular outcomes, including development of atrial arrhythmias, atrioventricular block, HF hospitalization, and stroke (3, 4) . Data from the ATTR-ACT (Transthyretin Amyloidosis Cardiomyopathy Clinical Trial) showed that patients with NYHA functional class III had an attenuated benefit from tafamidis compared with those with better NYHA functional classes, which emphasized the need for early detection and treatment of ATTR-CM (1) . Worse performance on other functional tests, such as the 6-min walk test, was also associated with worse survival (5) . shown to be an incrementally poor prognostic factor in patients with severe aortic stenosis (11, 12) .
Renal dysfunction was also identified as a risk remained even after controlling for biomarker-based staging (see the following) (5, 13) . Patients with the V122I variant also had shorter survival times from onset of cardiac symptoms to diagnosis, which potentially signaled a more pathogenic genotype (5) .
BLOOD BIOMARKERS
As Renal dysfunction and elevations in NT-proBNP were also recently found to be components of another robust prognostic staging system (13) . Patients with eGFR <45 ml/min/1.73 m 2 and NT-proBNP >3,000 pg/ml had significantly worse outcomes compared with those not meeting these thresholds.
Using a similar staging scheme to that previously described, the median survival was 5.7, 3.9, and 2.0 years for patients classified as Stages I, II, and III, respectively. The association of higher stage with worse survival remained significant even after the cohort was separated into different types of ATTR-CM (wild-type, V122I, or non-V122I).
Because of this dramatic difference in survival based on readily available, relatively inexpensive, and easily interpretable biomarkers in the context of these validated staging systems, it is important for clinicians to consider measuring these biomarkers during the initial workup for ATTR-CM in all patients. LGE has been found to be an independent predictor of worse survival for patients with either light-chain amyloid cardiomyopathy or ATTR-CM, even after adjustment for NT-proBNP and other echocardiographic measures (21) . Patients with subendocardial
IMAGING
LGE had better survival than those with transmural
LGE (3- year overall survival of approximately 80% vs. 50%, respectively). It was also demonstrated, using CMR T1 mapping, that increases in extracellular volume, a measure of amyloid burden that correlates with both the distribution of LGE and abnormal cardiac uptake on nuclear scintigraphy scans, was associated with worse survival (22) . 
